PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Department of Biomolecular Sciences, Weizmann Institute of Science, Rehovot, Israel.\', \'Chemogenomic and Biological Screening Core Facility, Institut Pasteur, Paris, France.\', \'Viral Populations and Pathogenesis Unit CNRS UMR 3569, Institut Pasteur, Paris, France.\', \'Department of Earth and Planetary Sciences, Weizmann Institute of Science, Rehovot, Israel.\', \'Department of Life Sciences Core Facilities, Weizmann Institute of Science, Rehovot, Israel.\', \'Department of Chemical Research Support, Weizmann Institute of Science, Rehovot, Israel.\', \'Bioqual, Rockville, MD, USA.\', \'Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA.\', \'Department of Biomolecular Sciences, Weizmann Institute of Science, Rehovot, Israel. gideon.schreiber@weizmann.ac.il.\']
?:citedBy
  • -1
?:creator
?:doi
?:doi
  • 10.1038/s41564-021-00954-4
?:hasPublicationType
?:journal
  • Nature microbiology
is ?:pmid of
?:pmid
?:pmid
  • 34400835
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 7.139
?:rankingScore_hIndex
  • 24
is ?:relation_isRelatedTo_publication of
?:title
  • SARS-CoV-2 variant prediction and antiviral drug design are enabled by RBD in vitro evolution.
?:type
?:year
  • 2021

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/34400835>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/34400835>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all